Reduced glomerular thromboxane receptor sites and vasoconstrictor responses in diabetic rats. Glomerular thromboxane production and urinary thromboxane excretion are increased in early diabetes, but in spite of this renal blood flow and glomerular filtration rate are significantly higher than in control animals. To study the possibility of a defect in thromboxane actions in the kidney, we have measured glomerular thromboxane receptors and the renal hemodynamic response to the administration of a stable thromboxane analog in diabetic rats. Glomerular thromboxane receptors were studied in hyperglycemic diabetic rats 7 to 10 days after injection of streptozotocin (65 mg/kg, iv.) and in normal controls. Scatchard analysis of equilibrium binding using the thromboxane antagonist, [3H]-SQ29548, demonstrated one class of high affinity thromboxane receptor sites in control (Kd = 19.9 2.6 nM, N = 16) and diabetic rats (Kd = 19.8 2.1 nsi, N 8, P NS). The number of thromboxane receptors was reduced by 44% in diabetic rats (control, 374 20 vs. diabetic, 210 21 fmol/mg, P < 0.01). Thromboxane binding in diabetic rats was not restored to normal levels by thromboxane synthetase inhibition with 0KY046. Diabetic rats had higher renal blood flow (diabetic, 7.03 0.18 vs. control, 6.33 0.13 mi/mm, P < 0.05) and glomerular filtration rate (2.42 0.10 vs.
The mechanisms leading to diabetic hyperfiltration are not known. However, it is likely that abnormal hormone-receptor interactions play a significant role. Angiotensin II receptors are reduced in the diabetic glomerulus at the time that hyperfiltration occurs [5] [6] [7] , Elevation of plasma angiotensin II levels either by intrarenal infusion or sodium depletion corrects hyperfiltration [8] , suggesting that the reduced receptor density relative to the availability of endogenous angiotensin II may play a role in the hyperfiltration.
Data from several laboratories demonstrate that diabetic glomeruli and aortae produce larger amounts of PGE2, PG!2 and thromboxane than normal glomeruli, and it has been postulated that excessive amounts of vasodilator prostaglandins contribute to the hyperfiltration [9] [10] [11] [12] [13] . Less attention has been given to possible abnormalities in the relationship between glomerular thromboxane, thromboxane receptors and renal responses to thromboxane in diabetes. In early diabetes thromboxane excretion is increased in the urine [14] [15] [16] [17] , but in spite of this renal blood flow and glomerular filtration rate are significantly higher than in control animals. To determine whether changes in thromboxane action contribute to diabetic hyperfiltration, we have measured glomerular thromboxane receptors, and the renal hemodynamic response to the administration of a stable analog of thromboxane in diabetic rats.
Methods Protocols
Thromboxane receptor studies. Experiments were performed on adult male Sprague-Dawley rats (324 10 g) fed standard rat chow (Ralston Purina Co., Chicago, Illinois, USA) (sodium ash content 0.42%) and given tap water to drink ad libitum. Diabetes was induced by the injection of streptozotocin (65 mg/kg i.v.) into the jugular vein of ether anesthetized rats. Normal rats injected with vehicle alone served as controls. The induction of diabetes was confirmed 24 hours later by semiquantitative urinary glucose measurements (Ames dipstick). Half of the diabetic rats were injected subcutaneously with 10 U NPH insulin daily (treated diabetics) and the other half were untreated. Quantitative blood glucose measurements were performed at the time of receptor measurements 7 to 10 days after streptozotocin injection.
The relationship between thromboxane production and gbmerular thromboxane binding was studied in four groups of rats: normal, diabetic (untreated), normal plus the thromboxane synthetase inhibitor, 0KY046 and diabetic plus 0KY046.
0KY046 treatment (20 mg/kg, s.c., b.i.d.) was begun immediately after streptozotocin or vehicle injection. Five days later six rats from each group were placed in metabolic cages, and urine was collected for the determination of TxB2 excretion on days six to seven as described below. At one week the binding of [3H]-SQ29548 to isolated glomeruli (75 g) was measured at a single concentration of ligand (20 nM) .
Additional normal rats were studied to determine the effects of thromboxane agonist infusion on glomerular thromboxane receptors. U466l9 (1.75 p.g/kg/min) was infused for 30 minutes into conscious rats via catheters (PE1O) previously placed into the aorta at the level of the renal arteries as described in detail [18] . Rats were decapitated and the kidneys were removed for glomerular thromboxane receptor measurements. U46619 reduced renal blood flow by 70% [18] , but did not significantly increase mean arterial pressure (baseline, 108 7 vs. U46619 infusion, 116 9mm Hg, P = NS).
Thromboxane receptor measurements. Rats were killed by decapitation and glomeruli were isolated for binding studies. The kidneys from three rats were pooled to obtain sufficient glomeruli for each binding experiment. The kidneys were immediately placed in chilled Tris-saline buffer (50 mrvi Tris in 0.154 M NaCl, 4°C, pH 7.5). The outer cortex was dissected, minced to a paste-like consistency and resuspended in buffer. Glomeruli were isolated by graded sieving using 90 m, 180 pm, 150 jtm and 75 sm stacked phosphor bronze sieves as previously described [18] . The cortical paste was pushed through the 90 m sieve onto the 180 pm sieve and washed through with 50 ml of buffer. The glomeruli retained on the 75 m sieve were >95% pure as determined by light microscopy. The number of gbomeruli in 20 il of glomerular suspension was counted in duplicate. Glomerular protein content was determined using the method of Lowry et al [19] .
Aliquots of glomeruli (75 j.g of protein) were incubated in a section. For hemodynamic studies the diabetic rats were divided into three groups. One group of animals (N = 5) was given NPH insulin, 2 to 3 U subcutaneously every other day to attenuate polyuria and polydipsia, but without attempting to normalize blood glucose (hyperglycemic diabetic rats). A second group of diabetic rats (N = 5; short-term euglycemic diabetic rats) was given 3.5 to 4.5 U Ultralente insulin subcutaneously at 3:00 PM on the day prior to the hemodynamic study. A third group of diabetic rats (N = 6) was injected with 3.5 to 4.5 U Ultralente insulin daily from the day after streptozotocin administration to the afternoon prior to study (longterm euglycemic diabetic rats). In these two latter groups, blood glucose was within the normal range at the time of hemodynamic measurement. A fourth group of normal rats (N = 5) served as non-diabetic controls. All experiments were performed 7 to 10 days after the induction of diabetes.
The rats were anesthetized with mactin (100 mg/kg body wt, i.p.) and prepared surgically for micropuncture study as previously described [7, 8, 22] . The left kidney was isolated, the renal artery exposed, and an ultrasonic flow probe (Transonic Systems, Inc., Ithica, New York, USA) was placed around the artery for continuous monitoring of renal blood flow. This method of blood flow measurement has been shown to be independent of vessel diameter [23] . In separate experiments, blood flow was stopped by clamping the renal artery to test the zero point. The reading fell to 0 to 0.2 mI/mm indicating an accurate zero point. A PE 10 polyethylene catheter was passed from a femoral artery into the abdominal aorta until it could be seen in the aorta 1 cm above the renal arteries. The location was confirmed by bolus injection of a small volume of F D and C green dye, which resulted in a flush of the kidneys. Priming and sustaining amounts of '4C-inulin (E.I. DuPont de Nemours & Co., Inc./NEN Products, Boston, Massachusetts, USA) were infused i.v. via a jugular vein catheter.
Renal blood flow was measured continuously, and after timed urine and proximal tubular fluid samples were obtained, U46619 was infused continuously into the abdominal aorta catheter at a rate of 0.1 g/min/kg body weight. Repeat urine and proximal tubular fluid collections were started 15 minutes later. Urine was collected from the urinary bladder for measurement of 14C-inulin and volume and the same measurements were carried out on proximal tubule fluid.
Arterial blood was collected periodically throughout the experiments from a carotid artery catheter, for measurement of 14C inulin concentration. Whole kidney glomerular filtration rate (GFR) and single nephron glomerular filtration rate (SNGFR) were calculated from standard equations [7, 81. Renal hemodynamic response to thromboxane receptor antagonist SK&F 96148
In four hyperglycemic diabetic rats treated every other day with 2 to 3 U NPH insulin, the renal response to intra-aortic infusion of a thromboxane receptor antagonist was measured. The surgical preparation of the animals was the same as in the preceding group. During a control period, RBF, GFR, and SNGFR were measured as described above. Following this, the thromboxane receptor antagonist, SK&F 96148, was injected into the abdominal aorta catheter in an initial dose of 1 mg/kg, followed by a continuous infusion of 1 mg/kg/hr. We have previously found that this dose of SK&F 96148 given to normal rats has no effect on MAP or GFR and only a small effect to increase RBF by 3.5% [221. Renal blood flow, GFR, and SNGFR measurements were repeated during the infusion of the thromboxane receptor antagonist.
Meausrement of urinary TxB2. Two studies were performed to measure urinary TxB2 excretion. In one study timed overnight urine collections were obtained in normal and diabetic rats treated intermittently with 1 to 2 U of NPH insulin. The urine was collected into vials containing 0.3 iM meclofenamate and frozen at -70°C until assayed. An enzyme immunoassay for TxB2 ws used, as described previously [221 using a TxB2 antibody kindly provided by Dr. P. Pradelles [24] . In a second study we determined the effects of the thromboxane synthetase inhibitor, 0KY046, on urinary thromboxane excretion, In brief, 24 hour urines were collected from normal and diabetic rats (without insulin treatment). Half of each group was treated with 0KY1J46 as described above and urines were stored at -70°C until assay. Urine was extracted using SepPak cartridges [251 and TxB2 quantitated by radioimmunoassay as previously described using a commercial TxB2 antibody (Advanced Magnetics Co., Cambridge, Massachusetts, USA) [26] . All samples were analyzed at the same time in order to avoid interassay variations.
Data analysis. Data are presented as the mean standard error. In the micropuncture experiments average data from the control period and from the experimental period were used in paired t-test analysis. All other data analysis was performed by ANOVA followed by the Student-Newman-Keuls method for multiple comparisons using the SAS program on an IBM AT computer. Where appropriate the Wilcoxon ranks sum test was used. The null hypothesis was rejected when the P <0.05.
Materials. Thromboxane B2 was purchased from Upjohn Diagnostics (Kalamazoo, Michigan, USA). Urinary thromboxane excretion in diabetic rats Urinary TxB2 excretion was increased in diabetic rats. Using an enzyme linked immunoassay on overnight urine collections, normal rats excreted 133 12 ng/kg/24 hr and diabetic rats excreted 241 21 nglkg/24 hr of TxB2, (P < 0.01). A second independent determination of urinary thromboxane excretion by radioimmunoassay gave overall lower values for urinary thromboxane excretion. However, the data from radioimmunoassay confirmed the rise in urinary thromboxane excretion in diabetic rats (see below).
Effects of thromboxane synthetase inhibition on glomerular thromboxane receptors If the reduced number of thromboxane receptors in diabetes was due to homologous downregulation by increased thromboxane levels, inhibition of thromboxane production with 0KY046 would be expected to prevent the reduction in receptors. As shown in Table 1 , 0KY046 reduced 24-hour thromboxane excretion by 49% in normal rats. Untreated diabetic rats had a doubling of urinary thromboxane excretion. The administration of 0KY046 to diabetic rats prevented the increased excretion of thromboxane: urinary TxB2 levels in 0KY046-treated diabetics were indistinguishable from TxB2 excretion in normal controls. Despite maintenance of normal urinary TxB2 excretion in diabetic rats treated with 0KY046, there was a 40% reduction in specific binding of [3H1-SQ29548 compared with normal untreated rats (P < 0.05). Thromboxane binding was reduced in diabetic rats independent of levels of urinary (10) Effect of glycemic control on renal hemodynamics. Table 2 shows data from normal, hyperglycemic, and diabetic rats treated with Ultralente insulin for either 18 hours or 7 to 10 days before study. The hyperglycemic animals had significantly higher RBF, GFR and SNGFR than the normal controls. The diabetic rats that received a single dose of Ultralente insulin 18 hours prior to study were euglycemic on the day of study. GFR and SNGFR remained higher than in the normal rats, although RBF was decreased to a value not different from the normal rats. In diabetic rats treated with daily injections of Ultralente insulin for 7 to 10 days, RBF, GFR, and SNGFR were all comparable to values in the normal rats. These observations are in agreement with those of Jensen Ct al [27] .
Effects of thromboxane agonist on renal hemodynamics
The effects of intra-aortic infusion of the thromboxane agonist, U46619, on renal hemodynamics are shown in Table 3 and Figure 3 . A low dose of U46619 was used (0.1 g/min/kg body wt) which caused a 20% reduction in whole kidney GFR and RBF, and a 25% reduction in SNGFR in normal rats. In the hyperglycemic diabetic rats, the same dose of U46619 produced only a 12% fall in GFR and RBF, and a 14% fall in SNGFR. The differences between the two groups were statistically significant. In sharp contrast in the diabetic rats treated with UItralente insulin for 18 hours before study to normalize blood glucose, the renal response to U46619 was indistinguishable from that in normal rats, When expressed as absolute changes (Table 3) , the response to U46619 was also statistically different in the three groups. Thus, GFR fell 0.38 0.03 ml/min in the normal rats versus 0.26 0.04 mI/mm in the hyperglycemic diabetics; RBF fell 1.21 0.15 mI/mm in the normals versus 0.69 0.18 ml/min in the hyperglycemic diabetics. The absolute values of SNGFR also fell to a lesser extent in the hyperglycemic diabetics, but the data did not reach statistical significance.
In the euglycemic diabetic rats, the absolute decrements in RBF, GFR and SNGFR were all significantly greater than in the hyperglycemic diabetic rats. As noted in Table 3 there were no significant changes in mean arterial pressure in any of the groups infused with U466l9.
Effect of thromboxane receptor antagonist on renal hemodynamics The results of measurements of RBF, GFR, and SNGFR in hyperglycemic diabetic rats before and during intra-aortic infusion of the thromboxane receptor antagonist, SK&F 96148, are Hyperglycemic diabetic (5) Table 4 . There was a small but statistically significant rise in all three measurements, ranging from 9 to 13%. We previously found that the same dose of SK&F 96148 had little or no renal hemodynamic response in normal rats, but a much larger response (30 to 35%) was found in rats with increased endogenous thromboxane production due to hypercholesterolemia [221.
Discussion
Increased renal blood flow and glomerular filtration rate are consistently seen in early diabetes mellitus in humans and experimental animals and are postulated to be major factors in the pathogenesis of renal functional impairment in diabetes mellitus [1] . The renal glomerulus produces both vasodilator and vasoconstrictor eicosanoids which are made in increased amounts in diabetes [9-131. Since diabetic glomeruli produce increased amounts of the vasoconstrjctor eicosanoid thromboxane A2 [91 and urinary thromboxane excretion is elevated early in the course of diabetes in animals and patients [9, [14] [15] [16] [17] , there may be abnormalities in renal responsiveness to thromboxane in the diabetic kidney. These observations led us to hypothesize that in early diabetes, responsiveness to thromboxane in the renal microcirculation may be decreased due to reduced numbers of thromboxane receptors. Since diabetes is a systemic disorder we reasoned that changes in thromboxane receptors in renal glomeruli may reflect a more generalized abnormality in thromboxane receptors in the kidneys and at other vascular sites. Glomerular thromboxane receptors were measured in control and 7 to 10 day diabetic rats using the thromboxane antagonist, [3H]-SQ29548. Scatchard analysis of equilibrium binding demonstrated one class of high affinity thromboxane receptor sites which was virtually identical in affinity in diabetic compared to control rats. However, there was a 44% reduction in the number of thromboxane receptors in untreated diabetic rats (P < 0.01).
To determine whether the apparent failure of the kidney to respond to elevated levels of thromboxane was due to the reduction in receptor number we examined the renal hernodynamic response to an infusion of a stable thromboxane agonist, U46619, The dose of U466l9 used decreased RBF, GFR and SNGFR by approximately 20% in normal rats without affecting blood pressure. In hyperglycemic diabetic rats the fall in RBF, GFR and SNGFR was about 50% less than in the normal controls. This blunted response to the thromboxane agonist was apparent in absolute decrease as well as in percent decreases in RBF and GFR. The data clearly demonstrate, therefore, that renal thromboxane responsiveness is reduced in hyperglycemic diabetic rats, which is consistent with the view that the decrease in thromboxane receptor number is responsible for the failure to respond to exogenous thromboxane. However, it is also possible that receptor occupancy by endogenous TxA2 may have been increased, and this was the reason for the blunted response to infusion of U46619. This possibility cannot be ruled out by the present observations. However, the fact that infusion of the TxA2 receptor antagonist SK & F 96148 caused only a modest rise in GFR and RBF (9 to 13%; SNGFR, Additional evidence linking the above abnormalities in hyperfiltration, thromboxane receptors and thromboxane responsiveness in the renal microcirculatjon comes from the experiments in which insulin normalized blood glucose. When insulin was administered in doses sufficient to normalize blood glucose concentration for 7 to 10 days, renal hemodynainics, thromboxane receptors and renal responsiveness to thromboxane agonist returned to control values, In contrast, when blood glucose was normalized for only 18 hours before study, GFR and SNGFR were still significantly above normal control values, although the response to U466l9 infusion was indistinguishable from that in normal rats. Return of vascular responsiveness to thromboxane that accompanies glycemic control appears to precede complete normalization of renal hemodynamics implying that factors other than a thromboxane receptor deficit also contribute to the complex disorder of diabetic hyperfiltration. Although the evidence from these studies shows a strong relationship between the thromboxane receptor deficit and hyperfiltration in early diabetes, due to the complex nature of the control of GFR it is not possible to fully assess the relative role of the thromboxane receptor deficit compared with other hormone abnormalities for the pathogenesis of hyperfiltration.
There are no previous studies examining the effects of thromboxane agonist infusion on the number of renal, glomerular or vascular thromboxane receptor sites in the kidney.
Thromboxane receptors have been most extensively studied in platelet membranes. In platelet membranes, there is one report that receptors may undergo homologous down regulation in vitro [281. Platelet and vascular tissue are now known to have distinct subtypes of thromboxane receptors [291, raising the possibility that factors that regulate one group of receptor sites may not regulate the other. In our study chronic inhibition of thromboxane production with 0KY046 did not significantly change the thromboxane binding in glomeruli from normal or diabetic rats. In a small group of experiments (N = 4), the acute infusion of a stable thromboxane agonist, U46619, did not cause thromboxane receptor downregulation. Although other receptor sites for vasoactive peptides such as angiotensin II [301 and endothelin-1 [31] down regulate in response to acute agonist infusion, it is possible that glomerular thromboxane receptor sites require a longer time for down regulation. However, when these data are considered with the chronic data on thromboxane synthetase inhibition, it was not possible to demonstrate homologous down regulation of glomerular thromboxane receptor sites under the conditions of our experiments.
The deficit in glomerular thromboxane receptors in diabetic rats is similar to the defect which occurs in angiotensin II receptors. For both angiotensin II and thromboxane the affinity of specific receptor sites is preserved, but the number of sites is significantly reduced in hyperfiltrating diabetics [5, 6] . Recent evidence suggests that increases in protein kinase C induced by hyperglycemia may down regulate glomerular receptor sites for several vasoactive hormones and autacoids. Lee et a! [32, 33] and Craven and de Rubertis [34] have demonstrated that elevated glucose concentrations lead to an increase in protein kinase C activity, an enzyme now known to be involved in the regulation of cell surface receptors. In studies of endothelin receptors Cozza et al [35, 36] demonstrated that protein kinase C stimulation with the diacylglycerol analog phorbol 12-myrisate 13-acetate (PMA) decreased the number of endothelin receptors in C-6 and adrenal glomerulosa cells, an effect which could be blocked by the protein kinase C inhibitor, H-7. Similar data were obtained in studies of the effects of phorbol esters on angiotensin II and arginine vasopressin receptors in cultured vascular smooth muscle cells [37, 38] . These data suggest that there is a generalized mechanism for the decrements in a variety of cell surface receptors in diabetes: elevated glucose stimulates protein kinase C which in turn reduces the number of cell surface receptors. In addition, other data suggest that PMA may alter the expression of hormone action through mechanisms independent of receptor number [39] . The mechanism of increased prostaglandin production appears to be directly related to hyperglycemia. Williams, Tsai and Schrier [38] and Tesfamarian et al [40) demonstrated that raising glucose concentration increased thromboxane production in smooth muscle cells in cultures [39] and from isolated rabbit aorta [40] . Urinary TxB2 excretion is elevated in poorly controlled diabetes, but is normalized by insulin treatment [16] .
Thus, both the increase in thromboxane production and the decrease in thromboxane receptor number can be attributed to events initiated by hyperglycemia. The relationship between glomerular thromboxane production (and/or urinary excretion of thromboxane) and GFR may be complex, and vary with the duration of diabetes. The current studies examined this relationship only during the first week of diabetes at a time when hyperfiltration is apparent. Period I is the control period; period 2 is the intra-aortic infusion of SK & F 96148. a P < 0.02 by Student's paired t-test.
In conclusion, this study demonstrates that there are reduced numbers of thromboxane receptor sites and reduced renal responsiveness to thromboxane in diabetic rats early in the course of diabetes. Both the receptor deficit and reduced vascular responses are restored to normal when hyperglycemia is corrected with insulin treatment, The abnormality in thromboxane receptors is not likely to be due to homologous down regulation of glomerular thromboxane receptor sites by increased local levels of thromboxane, since inhibition of thromboxane production did not alter thromboxane binding properties. Therefore, increased renal thromboxane production in diabetes can not effectively limit GFR because of reduced receptor binding.
